Home » Newsletters » BioWorld Science

BioWorld Science

July 21, 2020

View Archived Issues

New phase III study evaluates long-term safety of linerixibat for cholestatic pruritus in PBC

Bristol-Meyers Squibb presents preclinical data for anti-CTLA-4 antibody BMS-986218

Studies of Taisho's LpxC inhibitor TP-0586532 show antibacterial efficacy in vitro and in vivo

GlaxoSmithKline begins phase I study of GSK-6097608 in advanced solid tumors

Tau-binding marker [18F]PI-2620 may allow early identification of progressive supranuclear palsy

ACE2 humanized mouse model for the study of SARS-CoV-2 infection, pathogenesis and treatment

Enrollment open in phase II study of MAU-868 to treat BK viremia in kidney transplant recipients

Preventing T-cell rejection

NMBS-1, a novel HPK1 inhibitor with promising immunomodulatory activity in cancer models

HH-2710 shows efficacy in xenograft models of MAPK-mutant tumors

DT-095895 demonstrates efficacy in syngeneic mouse models of cancer

Agios Pharmaceuticals divulges MAT2A inhibitors

FORMA Therapeutics patents USP1 inhibitors

GlycoMimetics synthesizes new LGALS3 inhibitors

RaQualia Pharma presents new SCN9A and SCN10A channel blockers

Daiichi Sankyo describes new RXR agonists

First patient dosed in pivotal phase II portion of LOTIS 3 study

Positive interim efficacy and safety data presented for BNZ-1

First-in-human study of anticoagulant ONO-7684 successful in healthy subjects

SERENITY I and SERENITY II pivotal studies meet primary and secondary endpoints

Hillstream Biopharma presents preclinical data for HSB-1216 in cancer

Three COVID-19 vaccines generate T-cell responses

Phase III study of Trikafta in cystic fibrosis meets primary and secondary endpoints

FDA clears IND for phase II study of NT-I7 with nivolumab in gastric cancers

Phase III CLARITY study of pimavanserin in MDD does not meet primary endpoint

Sorrento cleared to begin phase II study in U.S. with abivertinib for COVID-19

Goldfinch Bio begins phase IIa study of GFB-887 for renal diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...